Differential Diagnosis of Hypertension: A Comprehensive Guide for Accurate Assessment

Introduction

Hypertension, currently defined as systolic blood pressure (SBP) of 130 mm Hg or greater and/or diastolic blood pressure (DBP) exceeding 80 mm Hg, stands as a pervasive chronic health issue characterized by persistently elevated arterial pressure. It is a well-researched condition and a significant comorbidity contributing to severe health complications, including stroke, myocardial infarction, heart failure, and kidney failure. Although the definitions and classifications of hypertension have evolved, a consensus exists that consistent blood pressure readings of 140/90 mm Hg or higher necessitate treatment, typically aiming for a therapeutic target of 130/80 mm Hg or lower. This article delves into the Differential Diagnosis Of Hypertension, exploring its etiology, clinical presentation, evaluation methods, and management strategies. Understanding the nuances of differential diagnosis is crucial for effective patient care and preventing long-term health consequences.

Etiology of Hypertension

Essential hypertension, the most common form, is idiopathic, meaning its exact cause is unknown. However, several factors are implicated in its development. One prominent factor is dietary salt intake. Research suggests that increased salt consumption can elevate the risk of hypertension. Genetic predisposition to salt sensitivity also plays a role, with approximately 50% to 60% of individuals being salt-sensitive and thus more prone to developing hypertension. This genetic component underscores the complex interplay between lifestyle and inherent factors in the etiology of essential hypertension.

Epidemiology of Hypertension

Globally, hypertension affects over one billion adults, representing up to 45% of the adult population. This high prevalence is consistent across various socioeconomic levels and income groups. The incidence of hypertension increases significantly with age, affecting as much as 60% of individuals over 60 years old. The 2010 Global Health Survey in Lancet, analyzing data from 67 countries, identified hypertension as the leading cause of death and disability-adjusted life years worldwide since 1990. In the United States, hypertension is a major contributor to cardiovascular disease-related deaths, surpassed only by cigarette smoking as a preventable cause of mortality. Projections indicate that the number of individuals with hypertension may rise by 15% to 20%, potentially reaching 1.5 billion by 2025, highlighting the escalating global burden of this condition.

Pathophysiology of Hypertension

The development of hypertension is multifaceted, involving several interconnected physiological mechanisms. These include increased salt absorption leading to fluid volume expansion, dysfunction in the renin-angiotensin-aldosterone system (RAAS), and heightened activity of the sympathetic nervous system. These physiological changes result in increased total peripheral resistance and increased afterload on the heart, ultimately leading to sustained high blood pressure. Understanding these mechanisms is crucial for developing targeted therapeutic strategies to manage hypertension effectively.

History and Physical Examination in Hypertension Diagnosis

In many cases, hypertension is asymptomatic, often detected incidentally during routine blood pressure measurements. However, some individuals may present with symptoms indicative of end-organ damage, such as stroke-like symptoms, hypertensive encephalopathy, chest pain, shortness of breath, or acute pulmonary edema. The physical examination may not reveal specific signs beyond elevated blood pressure or occasional pedal edema. However, it’s important to look for clinical indicators of secondary hypertension, which can be suggested by:

• Coarctation of the aorta: Assess for radio-radial and radio-femoral pulse delays, blood pressure discrepancies between arms or a difference exceeding 20 mm Hg between upper and lower limbs.
• Aortic valve disease: Listen for a systolic ejection murmur or a fourth heart sound (S4).
• Renovascular disease or fibromuscular dysplasia (FMD): Auscultate for renal or carotid bruits.
• Polycystic kidney disease: Palpate for bilaterally enlarged kidneys.
• Endocrine disorders: Look for signs of hypercortisolism (thin skin, easy bruising, hyperglycemia) or thyroid disorders (palpable, painful, or enlarged thyroid).

The presence of an S4 heart sound suggests left ventricular hypertrophy and diastolic dysfunction, often associated with chronic hypertension. Lung rales or peripheral edema may indicate cardiac dysfunction and chronicity of hypertension.

Evaluation and Diagnostic Approach for Hypertension

The American College of Cardiology (ACC) recommends diagnosing hypertension based on at least two office blood pressure measurements taken on two separate occasions. The European Society of Cardiology/European Society of Hypertension (ESC/ESH) suggests taking three office BP readings, 1 to 2 minutes apart, and additional readings only if the initial two vary by 10 mm Hg or more. The average of the last two readings is then recorded as the blood pressure. Both guidelines emphasize using the higher BP readings for staging and treatment decisions.

Proper blood pressure measurement technique is essential. Patients should be seated quietly for at least 5 minutes before measurement, and the cuff should encircle 80% of the arm circumference to ensure accurate readings. Ambulatory blood pressure monitoring (ABPM) is considered the gold standard for diagnosing hypertension, especially for identifying masked hypertension and white-coat hypertension.

Evaluation should include assessing for end-organ damage through:

• 12-lead ECG: To detect left ventricular hypertrophy and assess cardiac rate and rhythm.
• Fundoscopy: To examine for retinopathy or maculopathy.
• Blood workup: Including complete blood count, ESR, creatinine, eGFR, electrolytes, HbA1c, thyroid profile, cholesterol levels, and serum uric acid.
• Urine albumin-to-creatinine ratio: To assess for kidney damage.
• Ankle-brachial index (ABI): If peripheral arterial disease is suspected.
• Imaging: Carotid Doppler ultrasound, echocardiography, and brain imaging may be considered when clinically indicated.

Differential Diagnosis of Hypertension: Identifying Secondary Causes

While essential hypertension is the most prevalent form, it is critical to consider secondary causes of hypertension, especially in patients at the extremes of age or those with atypical presentations. Differential diagnosis of hypertension is crucial to identify and manage underlying conditions that may be contributing to or causing the elevated blood pressure. Conditions to consider in the differential diagnosis include:

1. Renal Causes

• Renovascular Hypertension: This is often due to renal artery stenosis, commonly caused by atherosclerosis or fibromuscular dysplasia. It should be suspected in patients with sudden onset hypertension, hypertension resistant to multiple medications, or the presence of an abdominal bruit.
• Chronic Kidney Disease (CKD): Damaged kidneys can lead to fluid and sodium retention, as well as RAAS activation, resulting in hypertension. CKD is a common cause of secondary hypertension and should be evaluated in all hypertensive patients.
• Polycystic Kidney Disease (PKD): Enlarged kidneys due to cysts can compress renal vasculature and activate the RAAS, leading to hypertension. PKD is often diagnosed through imaging and family history.

2. Endocrine Causes

• Primary Aldosteronism: Excessive aldosterone production leads to sodium retention and potassium excretion, causing hypertension. Suspect this in patients with hypertension and hypokalemia.
• Pheochromocytoma: A rare tumor of the adrenal gland that secretes catecholamines, causing episodic or sustained hypertension, often accompanied by headaches, sweating, palpitations, and anxiety.
• Cushing’s Syndrome: Excess cortisol can cause hypertension, along with other characteristic features like weight gain, moon face, and striae.
• Hyperthyroidism and Hypothyroidism: Both thyroid disorders can affect blood pressure. Hyperthyroidism can cause systolic hypertension and increased heart rate, while hypothyroidism can lead to diastolic hypertension.
• Hyperparathyroidism: Elevated calcium levels can contribute to hypertension.

3. Cardiovascular Causes

• Coarctation of the Aorta: A congenital narrowing of the aorta, typically diagnosed in childhood but can be missed until adulthood. It causes upper extremity hypertension and lower extremity hypotension.
• Aortic Valve Disease: Aortic insufficiency can lead to systolic hypertension due to increased stroke volume.

4. Medication and Substance-Induced Hypertension

• Nonsteroidal Anti-inflammatory Drugs (NSAIDs): NSAIDs can cause sodium and fluid retention, increasing blood pressure.
• Oral Contraceptives: Estrogen-containing contraceptives can elevate blood pressure in some women.
• Decongestants: Pseudoephedrine and phenylephrine can raise blood pressure due to their vasoconstrictive effects.
• Antidepressants: Certain antidepressants, particularly SNRIs and MAOIs, can increase blood pressure.
• Cocaine and Amphetamines: These substances are potent stimulants that can cause significant hypertension.
• Herbal supplements: Some herbal supplements can interact with blood pressure or directly raise it.

5. Sleep Apnea

• Obstructive Sleep Apnea (OSA): Repeated episodes of hypoxia during sleep activate the sympathetic nervous system and RAAS, leading to hypertension. OSA is often underdiagnosed and should be considered, especially in obese patients with resistant hypertension.

6. Pregnancy-Induced Hypertension

• Preeclampsia and Eclampsia: Hypertension developing during pregnancy can be a sign of preeclampsia, a serious condition that can progress to eclampsia with seizures.

7. Other Causes

• Primary Hyperparathyroidism: Elevated calcium levels can contribute to hypertension.
• Hypercalcemia of other etiologies: Similarly, elevated calcium from any cause can affect blood pressure.
• Acute Stress and Pain: While transient, severe stress or pain can acutely elevate blood pressure and should be considered in the context of measurement.

A thorough history, physical examination, and targeted investigations are essential to differentiate between essential and secondary hypertension and to identify the specific underlying cause when secondary hypertension is suspected. This diagnostic clarity is vital for guiding appropriate and effective management strategies.

Treatment and Management of Hypertension

Hypertension management includes both non-pharmacological and pharmacological approaches. Lifestyle modifications are recommended for all individuals with elevated blood pressure, regardless of age, gender, comorbidities, or cardiovascular risk. Patient education is paramount and should emphasize weight management, salt restriction, smoking cessation, management of obstructive sleep apnea, and regular exercise. These lifestyle changes must be maintained lifelong for effective disease management.

Weight reduction, even modest, can significantly lower systolic blood pressure by 5 to 20 mm Hg. Smoking cessation, while not directly impacting blood pressure, is crucial for reducing long-term cardiovascular complications. Lifestyle modifications alone can reduce cardiovascular events by up to 15%.

Pharmacological therapy typically involves angiotensin-converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARBs), diuretics (thiazides), calcium channel blockers (CCBs), and beta-blockers (BBs). Drug selection is guided by patient age, race, comorbidities (renal dysfunction, LV dysfunction, heart failure, cerebrovascular disease), and guideline recommendations (JNC-8, ACC, ESC/ESH).

JNC-8 Recommendations: Primarily focus on initiating pharmacological therapy based on age and presence of diabetes or chronic kidney disease, with specific target blood pressure goals for different populations.

ACC Recommendations: Emphasize a risk-based approach, considering 10-year atherosclerotic cardiovascular disease (ASCVD) risk. Antihypertensive medications are generally started at BP ≥ 140/90 mm Hg, but lower thresholds may be considered for high-risk individuals (diabetes, CKD, ASCVD, or 10-year ASCVD risk ≥ 10%). The goal is to achieve BP < 130/80 mm Hg for most patients.

ESC/ESH Recommendations: Recommend initiating pharmacological therapy based on hypertension grade and the presence of hypertension-mediated organ damage (HMOD). Grade 2 or 3 hypertension warrants immediate medication, while Grade 1 hypertension may initially be managed with lifestyle changes unless HMOD or high CVD risk is present. Specific targets are set for elderly patients (≥ 80 years).

Renal denervation, an investigational interventional treatment for resistant hypertension, aims to ablate renal sympathetic nerve supply. However, clinical trials (SPYRAL, RADIANCE, SIMPLICITY-HTN) have yielded inconclusive results, and it remains under investigation.

Pertinent Studies and Ongoing Trials in Hypertension

Several landmark randomized controlled trials (RCTs) have shaped hypertension management guidelines. The SYST-EUR, HYVET, and SHEP studies were foundational for the JNC-8 recommendations. The SPRINT, HOPE-3, Gubbio population study, and Framingham heart study, among others, informed the ACC and ESC/ESH guidelines. Ongoing research continues to refine hypertension treatment strategies and explore new therapeutic approaches.

Treatment Planning and Long-Term Management

Polytherapy, using multiple antihypertensive medications, is often necessary and is endorsed by both ACC and ESC/ESH guidelines. Treatment approaches include initiating combination therapy upfront or using a stepwise approach, titrating one drug to maximum dose before adding another. Both strategies can be effective with good patient compliance. All guidelines recommend assessing blood pressure control 8 to 12 weeks after initiating or adjusting medication. Home blood pressure monitoring or ABPM is recommended at baseline and 3 months post-therapy initiation for ongoing monitoring.

Toxicity and Adverse Effect Management of Antihypertensive Drugs

Side effects of antihypertensive medications are generally mild and often resolve with dose adjustment or temporary discontinuation. Common side effects include hypotension, electrolyte imbalances, pedal edema (more common with CCBs), and renal dysfunction. ACEi and ARBs can cause renal dysfunction and electrolyte imbalances, particularly hyperkalemia and hyponatremia, requiring periodic monitoring of creatinine, potassium, and sodium levels. Severe side effects like symptomatic hyperkalemia, hyponatremia, syncope, or acute kidney injury necessitate drug discontinuation and inpatient management. Angioedema, a rare but potentially life-threatening side effect of ACEi and ARBs, requires immediate discontinuation and contraindicates future use of these drug classes.

Staging and Classification of Hypertension

Hypertension classification is crucial for guiding management. The ACC guidelines (2017) and ESC/ESH guidelines (2018) provide distinct classifications:

ACC 2017 Hypertension Classifications:

• Normal: SBP < 120 and DBP < 80 mm Hg
• Elevated: SBP 120-129 and DBP < 80 mm Hg
• Stage 1 Hypertension: SBP 130-139 or DBP 80-89 mm Hg
• Stage 2 Hypertension: SBP ≥ 140 mm Hg or DBP ≥ 90 mm Hg

ESC/ESH 2018 Hypertension Grades:

• Optimal: SBP < 120 mm Hg and DBP < 80 mm Hg
• Normal: SBP 120-129 mm Hg and/or DBP 80-84 mm Hg
• High Normal: SBP 130-139 mm Hg and/or DBP 85-89 mm Hg
• Grade 1 Hypertension: SBP 140-159 mm Hg and/or DBP 90-99 mm Hg
• Grade 2 Hypertension: SBP 160-179 mm Hg and/or DBP 100-109 mm Hg
• Grade 3 Hypertension: SBP ≥ 180 mm Hg and/or DBP ≥ 110 mm Hg
• Isolated Systolic Hypertension: SBP ≥ 140 mm Hg and DBP < 90 mm Hg (graded further by SBP range)

ESC/ESH also provides cut-offs for home and ambulatory blood pressure measurements, including daytime, nighttime, 24-hour, and home BP averages, which are slightly lower than office measurements.

The JNC-8 report (2014), while criticized, offered its classifications based on JNC-7 definitions:

JNC-8 Classifications:

• Normal: SBP < 120 mm Hg and DBP < 80 mm Hg
• Pre-Hypertension: SBP 120-139 mm Hg and DBP 80-89 mm Hg
• Stage 1 Hypertension: SBP 140-159 mm Hg and DBP 90-99 mm Hg
• Stage 2 Hypertension: SBP ≥ 160 mm Hg and DBP ≥ 100 mm Hg

Understanding these different classifications is important for interpreting guidelines and applying them in clinical practice.

Prognosis of Hypertension

The prognosis of hypertension is strongly linked to blood pressure control. Large meta-analyses demonstrate a significant increase in cardiovascular disease and vascular disease risk with rising blood pressure. For every 20 mm Hg increase in systolic BP and 10 mm Hg increase in diastolic BP, the risk of death from heart disease and stroke nearly doubles. Prognosis is favorable with adequate blood pressure control, which can delay or prevent complications. However, hypertension is a progressive condition, and even with management, complications may still develop over time.

Complications of Uncontrolled Hypertension

Uncontrolled hypertension can lead to a wide range of serious complications, including:

1. Coronary heart disease (CHD)
2. Myocardial infarction (MI)
3. Stroke (CVA), ischemic or hemorrhagic
4. Hypertensive encephalopathy
5. Renal failure (acute or chronic)
6. Peripheral arterial disease
7. Atrial fibrillation
8. Aortic aneurysm
9. Death (primarily from CHD, vascular disease, or stroke)

These complications underscore the importance of early detection, effective management, and diligent monitoring of hypertension.

Consultations and Multidisciplinary Approach

Resistant hypertension often requires a multidisciplinary approach. Consultation with a cardiologist, nephrologist, and hypertension specialist is recommended for complex cases. Patients may also benefit from psychosocial counseling and dietary guidance from nutritionists and dieticians to support lifestyle modifications and treatment adherence.

Deterrence and Patient Education for Hypertension

Hypertension is a chronic condition requiring lifelong management. Comprehensive patient education regarding lifestyle modifications and pharmacological therapy is crucial for achieving optimal blood pressure control and preventing complications. Emphasizing weight management, physical activity, and limiting alcohol, tobacco, and smoking are key strategies to reduce cardiovascular risk.

Enhancing Healthcare Team Outcomes in Hypertension Management

Nurses often play a critical role in identifying hypertension in emergency rooms and outpatient settings. Prompt recognition and referral to a physician are essential, as many hypertensive patients may be unaware of their condition. Effective interprofessional communication is vital, particularly for resistant hypertension, where a collaborative approach involving nurses, nurse practitioners, primary care physicians, cardiologists, nephrologists, and pharmacists is beneficial. This team approach ensures comprehensive patient care, monitors treatment adherence and potential adverse effects, and ultimately improves patient outcomes while reducing healthcare costs.

References

1.Frost CD, Law MR, Wald NJ. By how much does dietary salt reduction lower blood pressure? II–Analysis of observational data within populations. BMJ. 1991 Apr 06;302(6780):815-8. [PMC free article: PMC1669164] [PubMed: 2025704]

2.Guyton AC, Coleman TG, Cowley AV, Scheel KW, Manning RD, Norman RA. Arterial pressure regulation. Overriding dominance of the kidneys in long-term regulation and in hypertension. Am J Med. 1972 May;52(5):584-94. [PubMed: 4337474]

3.Fagard R, Brguljan J, Staessen J, Thijs L, Derom C, Thomis M, Vlietinck R. Heritability of conventional and ambulatory blood pressures. A study in twins. Hypertension. 1995 Dec;26(6 Pt 1):919-24. [PubMed: 7490149]

4.Warren HR, Evangelou E, Cabrera CP, Gao H, Ren M, Mifsud B, Ntalla I, Surendran P, Liu C, Cook JP, Kraja AT, Drenos F, Loh M, Verweij N, Marten J, Karaman I, Lepe MP, O’Reilly PF, Knight J, Snieder H, Kato N, He J, Tai ES, Said MA, Porteous D, Alver M, Poulter N, Farrall M, Gansevoort RT, Padmanabhan S, Mägi R, Stanton A, Connell J, Bakker SJ, Metspalu A, Shields DC, Thom S, Brown M, Sever P, Esko T, Hayward C, van der Harst P, Saleheen D, Chowdhury R, Chambers JC, Chasman DI, Chakravarti A, Newton-Cheh C, Lindgren CM, Levy D, Kooner JS, Keavney B, Tomaszewski M, Samani NJ, Howson JM, Tobin MD, Munroe PB, Ehret GB, Wain LV., International Consortium of Blood Pressure (ICBP) 1000G Analyses. BIOS Consortium. Lifelines Cohort Study. Understanding Society Scientific group. CHD Exome+ Consortium. ExomeBP Consortium. T2D-GENES Consortium. GoT2DGenes Consortium. Cohorts for Heart and Ageing Research in Genome Epidemiology (CHARGE) BP Exome Consortium. International Genomics of Blood Pressure (iGEN-BP) Consortium. UK Biobank CardioMetabolic Consortium BP working group. Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk. Nat Genet. 2017 Mar;49(3):403-415. [PMC free article: PMC5972004] [PubMed: 28135244]

5.NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19·1 million participants. Lancet. 2017 Jan 07;389(10064):37-55. [PMC free article: PMC5220163] [PubMed: 27863813]

6.Danaei G, Ding EL, Mozaffarian D, Taylor B, Rehm J, Murray CJ, Ezzati M. The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLoS Med. 2009 Apr 28;6(4):e1000058. [PMC free article: PMC2667673] [PubMed: 19399161]

7.Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005 Jan 15-21;365(9455):217-23. [PubMed: 15652604]

8.Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB, Gibbons R, Greenland P, Lackland DT, Levy D, O’Donnell CJ, Robinson JG, Schwartz JS, Shero ST, Smith SC, Sorlie P, Stone NJ, Wilson PW, Jordan HS, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC, Tomaselli GF., American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014 Jun 24;129(25 Suppl 2):S49-73. [PubMed: 24222018]

9.Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016 Mar 05;387(10022):957-967. [PubMed: 26724178]

10.Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, Woodward M, MacMahon S, Turnbull F, Hillis GS, Chalmers J, Mant J, Salam A, Rahimi K, Perkovic V, Rodgers A. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016 Jan 30;387(10017):435-43. [PubMed: 26559744]

11.SPRINT Research Group. Wright JT, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015 Nov 26;373(22):2103-16. [PMC free article: PMC4689591] [PubMed: 26551272]

12.Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA, Williamson JD, Wright JT. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018 May 15;71(19):e127-e248. [PubMed: 29146535]

13.Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I., ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018 Sep 01;39(33):3021-3104. [PubMed: 30165516]

14.Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ., National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003 May 21;289(19):2560-72. [PubMed: 12748199]

15.Lewington S, Clarke R, Qizilbash N, Peto R, Collins R., Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002 Dec 14;360(9349):1903-13. [PubMed: 12493255]

16.Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, White IR, Caulfield MJ, Deanfield JE, Smeeth L, Williams B, Hingorani A, Hemingway H. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people. Lancet. 2014 May 31;383(9932):1899-911. [PMC free article: PMC4042017] [PubMed: 24881994]